

# John Fanikos

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4415469/john-fanikos-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94  
papers

1,581  
citations

21  
h-index

38  
g-index

97  
ext. papers

2,055  
ext. citations

3.8  
avg. IF

4.8  
L-index

#	Paper	IF	Citations
94	Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1606-1617	59.2	162
93	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2060-2072	15.1	119
92	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 1198-1204	2.4	101
91	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2013</b> , 1, 83-97	0.9	95
90	Hospital costs of acute pulmonary embolism. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 127-32	2.4	84
89	87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S5-S5	1	78
88	Anticoagulation-associated adverse drug events. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 1136-42	2.4	68
87	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 15-31	5.1	66
86	Major bleeding complications in a specialized anticoagulation service. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 595-8	3	59
85	Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 247-50	3	50
84	Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 44-9	2.4	47
83	Medication errors associated with anticoagulant therapy in the hospital. <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 532-5	3	45
82	Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. <i>American Journal of Medicine</i> , <b>2010</b> , 123, 536-41	2.4	44
81	Long-term complications of medical patients with hospital-acquired venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 688-93	7	42
80	"Inactive" ingredients in oral medications. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	40
79	Patient education program for venous thromboembolism prevention in hospitalized patients. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 258-64	2.4	33
78	Impact of smart infusion technology on administration of anticoagulants (unfractionated Heparin, Argatroban, Lepirudin, and Bivalirudin). <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 1002-5	3	33

77	Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 100, 1130-1135	7	31
76	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <i>Drugs</i> , <b>2015</b> , 75, 1627-44	12.1	30
75	Adverse drug events in hospitalized cardiac patients. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 1465-9	3	27
74	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1015-1023	2.4	25
73	Reversal agents for use with direct and indirect anticoagulants. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, S27-48	2.2	20
72	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , <b>2016</b> , 129, S1-S29	2.4	19
71	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 27-35	7	18
70	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 46-52	3.3	15
69	Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1290-1299	15.1	15
68	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. <i>American Journal of Emergency Medicine</i> , <b>2016</b> , 34, 46-51	2.9	14
67	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619876030	3.3	12
66	Patient-reported Outcomes from A National, Prospective, Observational Study of Emergency Department Acute Pain Management With an Intranasal Nonsteroidal Anti-inflammatory Drug, Opioids, or Both. <i>Academic Emergency Medicine</i> , <b>2016</b> , 23, 331-41	3.4	12
65	The frequency of inappropriate nonformulary medication alert overrides in the inpatient setting. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2016</b> , 23, 924-33	8.6	12
64	Kratom from Head to Toe—Case Reviews of Adverse Events and Toxicities. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2019</b> , 7, 141-168	0.9	11
63	Efficacy and safety of novel anticoagulants compared with established agents. <i>Therapeutic Advances in Hematology</i> , <b>2011</b> , 2, 175-95	5.7	11
62	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. <i>American Journal of Medicine</i> , <b>2016</b> , 129, S89-S96	2.4	11
61	Venous thromboembolism prophylaxis for medical service—mostly cancer—patients at hospital discharge. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 1143-50	2.4	9
60	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1635-1654	15.1	9

59	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , <b>2020</b> , 133 Suppl 1, 1-27	2.4	7
58	Medication use evaluation: pharmacist rubric for performance improvement. <i>Pharmacotherapy</i> , <b>2014</b> , 34 Suppl 1, 5S-13S	5.8	7
57	Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in U.S. hospitals. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, 2037-43	2.2	7
56	Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1191-8	5.8	6
55	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , <b>2018</b> , 2, e33-e38	2.7	6
54	Biosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2013</b> , 1, 226-235	0.9	5
53	Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1137-1143	2.4	5
52	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. <i>Journal of Atrial Fibrillation</i> , <b>2016</b> , 9, 1481	0.8	5
51	Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E143-5	7.1	4
50	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 16-24	2.4	4
49	Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2017</b> , 17, 132-135	1.1	3
48	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. <i>American Journal of Emergency Medicine</i> , <b>2020</b> , 38, 1163-1170	2.9	3
47	Contemporary NSTEMI management: the role of the hospitalist. <i>Hospital Practice (1995)</i> , <b>2020</b> , 48, 1-11	2.2	3
46	Regulatory and Clinical Perspective on Biosimilars: a Comparison of the US and European Experiences. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2019</b> , 7, 111-117	0.9	2
45	Best Practices for Medication Utilization Evaluations in Postsurgical Pain Management. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2017</b> , 5, 33-40	0.9	2
44	Aligning pharmacy and health-system objectives to eliminate central-line-associated bacteremias. <i>American Journal of Health-System Pharmacy</i> , <b>2009</b> , 66, 2189-97	2.2	2
43	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 331-335	5.1	2
42	Management of a parenteral opioid shortage using ASHP guidelines. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> , 78, 426-435	2.2	2

41	Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 2005-2007	4	2
40	Opioid-Free Recovery After Hernia Repair with HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting: A Randomized, Open-Label Study. <i>Pain and Therapy</i> , <b>2021</b> , 10, 1295-1308	3.6	2
39	The Pharmacist Discharge Care (PHARM-DC) study: A multicenter RCT of pharmacist-directed transitional care to reduce post-hospitalization utilization. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 106, 106419 <sup>3</sup>	2.3	2
38	Drug formulary decision-making: Ethnographic study of 3 pharmacy and therapeutics committees. <i>American Journal of Health-System Pharmacy</i> , <b>2019</b> , 76, 537-542	2.2	1
37	Unfractionated Heparin and Low-Molecular-Weight Heparin <b>2018</b> , 31-57		1
36	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2018</b> , 6, 54-61	0.9	1
35	Why Does the Food and Drug Administration Need to Ban Kratom?. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2019</b> , 7, 169-174	0.9	1
34	An assessment of currently available i.v. push medication delivery systems. <i>American Journal of Health-System Pharmacy</i> , <b>2017</b> , 74, e230-e235	2.2	1
33	Risk factors for the assessment of patients with pulmonary embolism. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2006</b> , 4, 871-80	7.3	1
32	Parenteral Anticoagulants: Special Considerations in Patients with Chronic Kidney Disease and Obesity 241-290		1
31	Regulatory Impact on Thrombosis Treatment, Prevention, and Anticoagulant Use. <i>Hematology/Oncology Clinics of North America</i> , <b>2016</b> , 30, 1115-35	3.1	1
30	Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 315-321.e4 <sup>1</sup>	4.9	1
29	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 405-412	5.1	1
28	Cleveland Clinic International IV Robotics Summit. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> , 78, 800-805	2.2	1
27	Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> , 78, 1568-1575	2.2	1
26	Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.. <i>Journal of Medical Economics</i> , <b>2022</b> , 1-44	2.4	1
25	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , <b>2020</b> , 19, 178-186	1.3	0
24	The Reply. <i>American Journal of Medicine</i> , <b>2017</b> , 130, e365-e366	2.4	0

23	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , <b>2021</b> , 20, 103-107	1.3	0
22	ASHP Guidelines on Medication-Use Evaluation. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> , 78, 168-175	2.2	0
21	Stability of alteplase for ultrasound-facilitated catheter-directed thrombolysis. <i>Blood Advances</i> , <b>2021</b> , 5, 5283-5289	7.8	0
20	Regulatory, legislative, and policy updates with anticoagulant use. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 39, 273-87	5.1	
19	Invited Commentary: Initial Experience with Direct Oral Anticoagulants in the Perioperative Setting. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2016</b> , 4, 88-92	0.9	
18	Use of P2Y12 inhibitors among Medicaid beneficiaries between 2008 and 2018. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 539-541	5.1	
17	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2019</b> , 7, 118-126	0.9	
16	Submassive Pulmonary Embolism: Risk Evaluation and Role of Fibrinolysis. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2013</b> , 1, 236-246	0.9	
15	Prescribing Naloxone: Managing and Preventing Opioid-Related Overdoses. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2017</b> , 5, 11-15	0.9	
14	Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. <i>Journal of Medical Economics</i> , <b>2013</b> , 16, 1190-2	2.4	
13	Total Parenteral Nutrition Preparation for a Known Latex-Allergic Patient. <i>Hospital Pharmacy</i> , <b>2001</b> , 36, 746-749	1.1	
12	Visual compatibility of perphenazine with various antimicrobials during simulated Y-site injection. <i>American Journal of Health-System Pharmacy</i> , <b>1987</b> , 44, 574-575	2.2	
11	Stability of bacitracin solution frozen in glass vials or plastic syringes. <i>American Journal of Health-System Pharmacy</i> , <b>1987</b> , 44, 1125-1127	2.2	
10	Visual Compatibility of Famotidine with Commonly used Critical-care Medications During Simulated Y-site Injection. <i>American Journal of Health-System Pharmacy</i> , <b>1988</b> , 45, 1556-1557	2.2	
9	Characteristics of the ideal clinical pharmacy residency candidate: A survey of residency program directors and preceptors in Saudi Arabia.. <i>Saudi Pharmaceutical Journal</i> , <b>2022</b> , 30, 66-71	4.4	
8	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. <i>Blood</i> , <b>2011</b> , 118, 2062-2062	2.2	
7	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 158-160	5.1	
6	Implementation of Pharmacy Executive Quality and Safety Walkrounds at a Tertiary Academic Medical Center. <i>Hospital Pharmacy</i> , 001857872110101	1.1	

- 5 Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, **2021**, 52, 22-29 5.1
- 4 Non-Sterile to Sterile Compounding: An Unconventional Response During the COVID-19 Pandemic. *Journal of Pharmacy Practice*, **2021**, 8971900211017861 1.3
- 3 Assessment of the Impact of Nursing Interruptions on Pharmacist Workflow and Efficiency. *Hospital Pharmacy*, **2016**, 51, 49-53 1.1
- 2 Intravenous and Oral Hyperammonemia Management. *Current Emergency and Hospital Medicine Reports*, **2018**, 6, 182-193 0.9
- 1 Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review. *International Journal of Pharmaceutical Compounding*, **2020**, 24, 346-351 0.2